1-2 of 2
Jeroen van Velzen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Clinical Trials & Observations
Inger S. Nijhof, Laurens E. Franssen, Mark-David Levin, Gerard M. J. Bos, Annemiek Broijl, Saskia K. Klein, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber, Ellen van der Spek, Paula F. Ypma, Reinier Raymakers, Dick-Johan van Spronsen, Peter E. Westerweel, Rimke Oostvogels, Jeroen van Velzen, Berris van Kessel, Tuna Mutis, Pieter Sonneveld, Sonja Zweegman, Henk M. Lokhorst, Niels W. C. J. van de Donk
Journal: Blood
Blood (2016) 128 (19): 2297–2306.
https://doi.org/10.1182/blood-2016-07-729236
Published: 2016
Includes: Supplemental data
Journal Articles

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Clinical Trials & Observations
Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen, Berris van Kessel, Amy E. Axel, Khaja Syed, Richard W. J. Groen, Mark van Duin, Pieter Sonneveld, Monique C. Minnema, Sonja Zweegman, Christopher Chiu, Andries C. Bloem, Tuna Mutis, Henk M. Lokhorst, A. Kate Sasser, Niels W. C. J. van de Donk
Journal: Blood
Blood (2016) 128 (7): 959–970.
https://doi.org/10.1182/blood-2016-03-703439
Published: 2016
Includes: Supplemental data